Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
Mark R. Middleton(University of Oxford), N. Thatcher(Humboldt-Universität zu Berlin), A. Coates(Humboldt-Universität zu Berlin), ML Müller(Humboldt-Universität zu Berlin), Jonathan Cebon(La Trobe University), Dirk Schadendorf(National Center for Tumor Diseases), Gerhard Fierlbeck(Humboldt-Universität zu Berlin), Uwe Fraass(Humboldt-Universität zu Berlin), Jean‐Jacques Grob(Aix-Marseille Université), Amy V. Kapp(Humboldt-Universität zu Berlin), Steinar Aamdal(Humboldt-Universität zu Berlin), M. Henz(Humboldt-Universität zu Berlin), Neil K. Aaronson(The Netherlands Cancer Institute), Wolfgang Tilgen(Humboldt-Universität zu Berlin), J. Weiss(Humboldt-Universität zu Berlin), Simone Seiter(Humboldt-Universität zu Berlin), Brigitte Dréno(Nantes Université), Martin Gore(Imperial College London), Paul Statkevich(Humboldt-Universität zu Berlin)
Cited by 1,265
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries
|Journal of Clinical Epidemiology|1998|2.9k
EORTC QLQ-C30 Scoring Manual
|Research at the University of Copenhagen (University of Copenhagen)|1995|2.4k